LTB4R2
Leukotriene B4 receptor 2
As of the edition of 20 October 2026, LTB4R2 (leukotriene B4 receptor 2, UniProt Q9NPC1) has 2 drugs tested at it and 2 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9NPC1
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Disease areas
- Blood and lymph; Immune system; Skin and connective tissue; Bones, joints and muscles; Eye
- Registered trials of its drugs
- 8
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Nomacopan | Stopped | Phase 3 | none listed |
| CP-195543 | Stopped | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Pfizer | Route A |
| AKARI Therapeutics | Route A |
The other 0 companies at LTB4R2
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at LTB4R2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.